Drug Combination Details
General Information of the Combination (ID: C68221) | |||||
---|---|---|---|---|---|
Name | Silibinin NP Info | + | Mitoxantrone Drug Info | ||
Structure | + | ||||
Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The combination of silibinin and mitoxantrone exhibits a pattern of synergy in reducing cell viability with increased apoptosis. |
References | ||||
---|---|---|---|---|
Reference 1 | Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 1;120(9):2028-33. |